Lexeo Therapeutics (LXEO) Interest Coverage Ratio (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Interest Coverage Ratio of 8.09 for Q1 2026, up 27.3% sequentially from 11.13 in Q4 2025, and up 87.24% YoY from 4.32 in Q1 2025.
Powered by 
Analysis
Lexeo Therapeutics (LXEO) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Interest Coverage Ratio for 5 years, with the latest figure at 8.09 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 87.24% year-over-year to 8.09 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35.43 (down 110.69% YoY) and the FY2025 annual result came in at 0.92, up 94.54% from the prior year.
- Interest Coverage Ratio rose to 8.09 in Q1 2026 per LXEO's latest filing, from 11.13 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 78.74 in Q4 2022 and troughed at 299.48 in Q4 2023.
- A 5-year average of 28.55 and a median of 5.71 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio surged 106.35% in 2024, then plunged 4867.23% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 78.74 in 2022, then plunged by 480.34% to 299.48 in 2023, then jumped by 106.35% to 19.0 in 2024, then tumbled by 158.57% to 11.13 in 2025, then rose by 27.3% to 8.09 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 8.09, 11.13, and 2.49 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Lexeo Therapeutics | 419.14 Mn | 419.14 Mn | - | -2,001.43 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,001.43 |
| Mar 31, 2026 | -1,313.71 |
| Dec 31, 2025 | -1,155.80 |
| Sep 30, 2025 | -984.00 |
| Jun 30, 2025 | -1,227.52 |
| Mar 31, 2025 | -1,207.32 |
| Dec 31, 2024 | -912.73 |
| Sep 30, 2024 | -901.23 |
| Jun 30, 2024 | -672.86 |
| Mar 31, 2024 | -629.49 |
| Dec 31, 2023 | -299.48 |
| Sep 30, 2023 | -389.87 |
| Jun 30, 2023 | -263.68 |
| Mar 31, 2023 | -385.80 |
| Dec 31, 2022 | -281.43 |
| Sep 30, 2022 | -602.83 |